Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dyandra Media International Tbk PT
IDX:DYAN
|
ID |
|
Tianshui Zhongxing Bio-technology Co Ltd
SZSE:002772
|
CN |
|
V
|
Viol Co Ltd
KOSDAQ:335890
|
KR |
|
Chaoju Eye Care Holdings Ltd
HKEX:2219
|
CN |
|
A
|
Aris Water Solutions Inc
NYSE:ARIS
|
US |
|
S
|
SPSoft Inc
KOSDAQ:443670
|
KR |
|
Y
|
Yantai Changyu Pioneer Wine Co Ltd
SZSE:000869
|
CN |
|
Nexus Infrastructure PLC
LSE:NEXS
|
UK |
|
S
|
Silla SG Co Ltd
KOSDAQ:025870
|
KR |
|
G
|
Graubuendner Kantonalbank
SIX:GRKP
|
CH |
|
X
|
XL Holdings Bhd
KLSE:XL
|
MY |
|
V
|
Vertu Capital Ltd
LSE:VCBC
|
MY |
|
Plaza Retail REIT
TSX:PLZ.UN
|
CA |
|
B
|
Black Sesame International Holding Ltd
HKEX:2533
|
CN |
Novan Inc
Long-Term Debt
Novan Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Long-Term Debt
$39.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Long-Term Debt
$42.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
21%
|
|
|
Pfizer Inc
NYSE:PFE
|
Long-Term Debt
$61.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Long-Term Debt
$46.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Long-Term Debt
$40.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
20%
|
CAGR 10-Years
18%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Long-Term Debt?
Long-Term Debt
0
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Long-Term Debt amounts to 0 USD.
